<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83885">
  <stage>Registered</stage>
  <submitdate>4/05/2009</submitdate>
  <approvaldate>25/05/2009</approvaldate>
  <actrnumber>ACTRN12609000344291</actrnumber>
  <trial_identification>
    <studytitle>Improving Quality of Life (QOL) measurement for melanoma patients and their families</studytitle>
    <scientifictitle>Improving Quality of Life (QOL) measurement for melanoma patients and their families: Validity and reliability study of QOL insruments in an Australian sample</scientifictitle>
    <utrn />
    <trialacronym>MEL-QOL Research Study</trialacronym>
    <secondaryid>ANZMTG RP1.09</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Quality of Life (QOL) of melanoma patients and their families</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Malignant melanoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This is a questionnaire based study relying on participation at two levels. The first part of the study will involve conducting a set of focus group interviews with patients and their family members which will gather qualitative information about their experiences with melanoma diagnosis and treatment and how it has impacted on their quality of life (QOL). The focus group interviews would generally be 1-2 hour sessions and about 10 sessions in total would be held over a 3 month period (5 sessions for patients and 5 sessions for family members) depending on participant accrual. 

The second part of the study will involve participants completing a set of quality of life (QOL) questionnaires in addition to a composite set of new quality of life (QOL) items developed from the first part of the study. A set of 5 questionnaires would be distributed to each participant (patients and familiy members) and they would submit completed questionnaires on the day of the trial visit.</interventions>
    <comparator>None</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Generation and validation of new items for a melanoma-specific quality of life (QOL) instrument. The focus group interviews from the first part of the study will collect qualitative data on quality of life (QOL) isssues from patients and their family members. An interview template would be used to prompt discussions on quality of life (QOL) topics. Responses would be digitally recorded for transcription and qualitative analysis by the Biostatistician.</outcome>
      <timepoint>6 months post-focus group interviews</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>None</outcome>
      <timepoint>None</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>i) All melanoma patients attending clinics at Sydney Melanoma Unit (Melanoma Institute Australia), Sydney Cancer Centre (Royal Prince Alfred Hospital) and Westmead Cancer Care Centre (Westmead Hospital) 

ii) Participants must have sufficient English fluency</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>i) Patients with current major psychiatric disturbance or mental illness

ii) Participants with insufficient English fluency</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Psychosocial</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/07/2009</anticipatedstartdate>
    <actualstartdate>1/06/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate>31/12/2010</actualenddate>
    <samplesize>1060</samplesize>
    <actualsamplesize>1060</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>31/12/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>2060</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>The Australia and New Zealand Melanoma Trials Group (ANZMTG)</primarysponsorname>
    <primarysponsoraddress>Level 2
1A Eden St
North Sydney NSW 2060</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of Sydney</fundingname>
      <fundingaddress>Research Office
Level 6
Jane Foss Russell Building G02
Camperdown NSW 2006</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>University</othercollaboratortype>
      <othercollaboratorname>The Psycho-Oncology Co-operative Research Group (PoCoG)</othercollaboratorname>
      <othercollaboratoraddress>School of Psychology
Brennan MacCallum Building A18
Camperdown NSW 2006</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sydney South West Area Health Service (SSWAHS) Royal Prince Alfred Hospital Ethics Review Committee (RPAH Zone)</ethicname>
      <ethicaddress>Research Development Office 
Royal Prince Alfred Hospital 
Missenden Rd 
Camperdown NSW 2050</ethicaddress>
      <ethicapprovaldate>1/06/2009</ethicapprovaldate>
      <hrec>HREC/09/RPAH/124</hrec>
      <ethicsubmitdate>27/05/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>A/Prof Julie Winstanley</name>
      <address>Australia and new Zealand Melanoma Trials Group / Melanoma Institute Australia incorporating Sydney Melanoma Unit 
Level 2
1A Eden St
North Sydney NSW 2060</address>
      <phone>+61 2 9911 7271</phone>
      <fax>+61 2 9954 9435</fax>
      <email>julie.winstanley@smu.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>A/Prof Julie Winstanley</name>
      <address>Australia and new Zealand Melanoma Trials Group / Melanoma Institute Australia incorporating Sydney Melanoma Unit 
Level 2
1A Eden St
North Sydney NSW 2060</address>
      <phone>+61 2 9911 7271</phone>
      <fax>+61 2 9954 9435</fax>
      <email>julie.winstanley@smu.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Eshwini Tadiyal</name>
      <address>Australia and New Zealand Melanoma Trials Group
Level 2
1A Eden St
North Sydney NSW 2060</address>
      <phone>+61 2 9911 7352</phone>
      <fax>+61 2 9954 9435</fax>
      <email>anzmtg@usyd.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>A/Prof Julie Winstanley</name>
      <address>Australia and new Zealand Melanoma Trials Group / Melanoma Institute Australia incorporating Sydney Melanoma Unit Level 2 1A Eden St North Sydney NSW 2060</address>
      <phone>+61 2 9911 7271</phone>
      <fax />
      <email>julie.winstanley@smu.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>